How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Standard of Care More Likely to Be Cost-Effective Than CAR-T Therapy in DLBCL
Researchers sought to determine the cost-effectiveness of CAR-T therapy compared with standard of care in patients with DLBCL.
Elevated MTX Levels Linked With Clinical Outcomes in Lymphoma
Researchers sought to determine whether using high-dose methotrexate would lead to increased risks in patients with lymphoma.
Addition of Atezolizumab to Obinutuzumab-Bendamustine Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Researchers sought to determine whether adding atezolizumab to an obinutuzumab-bendamustine chemoimmunotherapy regimen would improve survival in FL.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Consolidative Stem Cell Transplant May Improve Outcomes Among Patients With PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Adcetris Approved for Pediatric Patients With High Risk Classical Hodgkin Lymphoma
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Lymphoma-Specific Questionnaire Addresses Unmet Patient Needs
Researchers developed an instrument to identify unmet needs and quality-of-life outcomes for patients with lymphoma.
Allo-HSCT May Be Promising Strategy in Relapsed or Refractory PMBCL
Researchers sought to determine whether allo-HSCT would be effective for inducing durable remission among patients with relapsed or refractory PMBCL.
UCBT With FM-Based Reduced-Intensity Conditioning Improved Survival in Lymphoma
Researchers sought to determine whether UCBT with FM-based reduced-intensity conditioning would improve survival outcomes in patients with lymphoma.
Ultra-Low-Dose Radiation Appears Effective in Orbital Indolent B-Cell Lymphoma
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
PD-L1 and YWHAZ Expression Linked to Prognosis in Diffuse Large B-Cell Lymphoma
Researchers sought to identify links between the expression of 2 proteins and prognosis in patients with diffuse large B-cell lymphoma.
Novel Therapies Present Opportunity to Improve Outcomes for Patients With Richter Transformation
Researchers sought to identify novel therapeutic approaches to patients who develop Richter transformation.
Bendamustine Plus Rituximab Appears Effective in Treating First-Line, Transplant-Eligible Mantle Cell Lymphoma
Researchers sought to determine whether first-line rituximab plus bendamustine followed by ASCT would be an effective treatment option for MCL.
MRD Persistence Is Associated With Increasing Risk for Relapse of Mantle Cell Lymphoma
Researchers sought to determine whether MRD may predict relapse risk in patients with MCL.
Immune Responses to SARS-CoV-2 mRNA Vaccines Vary Among Patients With Hematologic Malignancies
Researchers sought to determine the vaccination-induced immune responses among patients with hematologic malignancies.
Risk Prediction Models Identify Hodgkin Lymphoma Survivors at Risk for CVD
Researchers sought to determine risk predictors for coronary heart disease and heart failure in Hodgkin lymphoma survivors who were aged 18 to 50 at diagnosis.
Tisagenlecleucel Plus Pembrolizumab May Be Effective in Patients With R/R Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether CAR-T therapy following pembrolizumab treatment would be effective in patients with relapsed/refractory DLBCL.
Validation of a New Prognostic Tool in Aggressive Large B-Cell Lymphoma
Researchers sought to validate a new prognostic tool for patients with aggressive large B-cell lymphoma.
Cutaneous T-Cell Lymphoma Incidence on the Rise in the United States
The incidence of cutaneous T-cell lymphoma in the United States increased from 2000 to 2018, with an annual percent change of 0.61%.
PLM60 Plus Pegaspargase Shows Promise in Extranodal Natural Killer and T-Cell Lymphoma
Researchers sought to determine whether PLM60 with pegaspargase would have efficacy in patients with extranodal natural killer/T-cell lymphoma.
Orelabrutinib Plus RCHOP Effective for Extranodal, Non-GCB Diffuse Large B-Cell Lymphoma
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib with RCHOP in patients with extranodal non-GCB DLBCL.
Long-Acting G-CSF May Reduce FN-Related Hospitalization in DLBCL After R-CHOP
Long-acting G-CSF can reduce the risk of hospitalization related to febrile neutropenia in patients with DLBCL treated with R-CHOP.
Genomic Features and Anti-CD19 CAR-T Therapy Failure in Large B-Cell Lymphoma
Researchers sought to identify genomic features in patients with large B-cell lymphoma that are linked with anti-CD19 CAR-T therapy.
Management and Survival Outcomes of Waldenström Macroglobulinemia in Latin America
Researchers sought to determine the clinical, therapy, and outcome patterns of patients with WM in Latin America.
Coagulation Parameters With Cytokine-Release Syndrome and CAR-T Therapy in B-Cell Lymphomas
Researchers sought to determine patterns in coagulation parameters linked to cytokine-release syndrome in patients receiving CAR-T therapy.
First-Line Brentuximab Vedotin With AVD Improves Survival in Stage III or IV Hodgkin Lymphoma
Researchers sought to determine whether adding brentuximab vedotin to AVD would improve survival in patients with stage III or IV Hodgkin lymphoma.
Acute Kidney Injury After CAR-T Therapy for Non-Hodgkin Lymphoma
Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Real-World Analysis Reveals Treatment, Survival Trends in Mantle Cell Lymphoma
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
Cytopenias After Axicabtagene Ciloleucel Therapy for Large B-cell Lymphoma
Rates and patterns of development of severe cytopenias in patients after axicabtagene ciloleucel therapy for large B-cell lymphoma were identified.
TPO Receptor Agonist for CAR-T-Associated Persistent Cytopenia
TPO receptor agonist treatment for severe persistent cytopenia associated with CAR-T therapy resulted in complete cytopenia remission among most patients.
Novel Transcriptomic Subclassification Approach for PTCL Developed
Researchers sought to develop a gene expression-based subclassification for improved PTCL diagnosis.
First-Line Brentuximab Vedotin Plus AVD Shows Promise in Early-Stage Unfavorable Hodgkin Lymphoma
Researchers sought to determine whether brentuximab vedotin plus AVD would improve responses in patients with previously untreated, early-stage unfavorable HL.
Long-Term Results of Radiotherapy Vs ASCT for Primary CNS Lymphoma in Older Patients
The researchers sought to evaluate the long-term outcomes and toxicities of the treatments in the PRECIS study.
Usefulness of Bone Marrow Biopsy in Follicular Lymphoma Clinical Trials Questioned
Researchers investigated a hypothesis that posttreatment bone marrow biopsy may not be needed after confirming complete response on imaging in patients with follicular lymphoma.
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.
Third Dose of COVID-19 Vaccine Appears Least Effective for Lymphoma Patients
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Targeted Radiotherapy Remains Important in Pediatric Hodgkin Lymphoma With Slow Early Response to Chemotherapy
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Mosunetuzumab Demonstrates Activity in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab produced an objective response rate of 80%.
Response-Adapted Nivolumab Salvage Therapy Safe and Effective in Classical Hodgkin Lymphoma
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Low Adoption of SC-RT for Lymphoma Among Medicare Beneficiaries
Researchers sought to determine the trends in the utilization of Medicare on short-course radiotherapy in patients with lymphoma.
Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Pola-R-CHP May Be Cost Effective, Depending on PFS Outcomes in Previously Untreated DLBCL
Researchers sought to determine whether the combination pola-R-CHP would be cost-effective for treating patients with previously untreated DLBCL.
Real-World Treatment Outcomes, Roles of Transplantation and Maintenance Rituximab in Mantle Cell Lymphoma
Researchers sought to determine the role and utilization of ASCT in younger patients with MCL.
Generic Equivalent to Istodax Now Available
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.
Predicting Disease Progression in Patients With MALT Lymphoma
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...